Therapeutic effects of S-35-thiouracil in balb/c mice carrying harding-passey melanoma

R. G. Fairchild, J. A. Coderre, S. Packer, D. Greenberg, B. H. Laster

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Thiouracil (TU) selectively binds to the pigment melanin during melanogenesis and is rapidly cleared from normal tissues. This compound shows little affinity for pre-formed melanin. BALB/c mice, carrying the subcutaneously transplanted Harding-Passey melanoma, were given i.p. injections of 35S-labeled thiouracil in a range of doses and administration schedules. Injected doses ranged from 1.3 to 10 mCi per mouse with resultant tumor dose rates of 10 to 30 cGy/hr, respectively. At the lower dose rates, growth delay of ∼1 to 2 weeks was observed in all tumors. At the highest doses used, complete tumor regression (no regrowth) was observed in some cases, with extended growth delays of ∼6 weeks in the rest. These results illustrate the possible utility of radiolabeled thiouracil as a systemically administered brachytherapy agent for melanoma.

Original languageEnglish
Pages (from-to)337-343
Number of pages7
JournalInternational journal of radiation oncology, biology, physics
Issue number2
StatePublished - 1 Jan 1989
Externally publishedYes


  • Brachytherapy
  • Harding-Passey melanoma
  • Thiouracil

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Therapeutic effects of S-35-thiouracil in balb/c mice carrying harding-passey melanoma'. Together they form a unique fingerprint.

Cite this